

MINISTRY OF HEALTH- REPUBLIC OF ZAMBIA

Zambia: ARV Drug Logistics System Assessment Results & Recommendations





JULY 2010

This publication was produced for review by the U.S. Agency for International Development. It was prepared by the USAID | DELIVER PROJECT, Task Order 4.



Zambia: ARV Drug Logistics System Assessment Results & Recommendations

October 2009

USAID | DELIVER PROJECT, Task Order 4

The USAID | DELIVER PROJECT, Task Order 4, is funded by the U.S. Agency for International Development (USAID) under contract number GPO-I-00-06-00007-00, order number AID-OAA-TO-10-00064, beginning September 30, 2010. Task Order 4 is implemented by John Snow, Inc., in collaboration with Asociación Benéfica PRISMA; Cargo Management Logistics; Crown Agents USA, Inc.; Eastern and Southern African Management Institute; FHI360; Futures Institute for Development, LLC; LLamasoft, Inc; The Manoff Group, Inc.; OPS MEND, LLC; PATH; PHD International (a division of the RTT Group); and VillageReach. The project improves essential health commodity supply chains by strengthening logistics management information systems, streamlining distribution systems, identifying financial resources for procurement and supply chain operation, and enhancing forecasting and procurement planning. The project encourages policymakers and donors to support logistics as a critical factor in the overall success of their healthcare mandates.

Recommended Citation

Mwango, Dr. Albert, John C. Sikasote, Wendy Nicodemus, Yapoma Nkhoma, Chileshe Banda, Evans Mwape, Natasha K Matafwali and Daison Machinyise. 2010. Zambia: ARV Drug Logistics System Assessment Results & Recommendations. Arlington, VA.: USAID | DELIVER PROJECT, Task Order 4.

Abstract

In October 2009, the Ministry of Health (MOH), with technical assistance from the USAID | DELIVER PROJECT, Task Order 1, and support from other partners, conducted an assessment of the performance of the ARV drug logistics system in Zambia.

The survey's overall purpose was to assess the performance of the system since its roll-out, to identify successes and challenges in the system, and to provide necessary recommendations to improve the system. This report presents the findings of the assessment as well as recommendations for improving the ARV drug logistics system in Zambia.

USAID | DELIVER PROJECT

John Snow, Inc. 1616 Fort Myer Drive, 11th Floor Arlington, VA 22209 USA Phone: 703-528-7474 Fax: 703-528-7480 Email: askdeliver@jsi.com Internet: deliver.jsi.com

Ministry of Health

National ARV Programme Ndeke House P.O. Box 30205 Lusaka Phone : +260 211 253040 ps@moh.gov.zm

Contents

Acronyms	v
Acknowledgments	vii
Executive Summary	ix
Overview of the ARV Drug Logistics System	I
Purpose of the ARV Drugs Logistics System Assessment	5
Methodology	7
Findings	9
Human Resources	9
LMIS Records and Reports	10
Stock Availability	10
Transport	
Storage	12
ART Satellite Sites: Biggest Challenge to ARV Logistics System	
Discussion	
Impact of ART Satellite Sites on the System	15
Outcome of the dissemination meeting concerning the ART Satellite Sites	15
Challenges	
Conclusion and Recommendations	17
References	
Appendices	
A. LMIS Forms	21
B. Data Collection FormsARV Logistics System	31
Figures	
I. Movement of ARV Drugs and Information	2
2. 181 Full ART Sites as of October 2009	
3. ART Sites Evaluated	7
4. Personnel Managing ARV Logistics System	9
5. Stockouts of Indicator Drugs in Full ART Sites	
6. Distribution and Collection of ARV Drugs	
7. ART Satellite Sites Assessed	12
8. Stockouts of Indicator Drugs at ART Satellite Sites	

Acronyms

AIDS	acquired immunodeficiency syndrome
ART	antiretroviral therapy
ARV	antiretroviral (drug)
AZT	Zidovudine
CHAZ	Churches Health Association of Zambia
CIDRZ	Center for Infectious Disease Research in Zambia
DHMT	district health management team
DHO	district health office
HIV	human immunodeficiency virus
JSI	John Snow, Inc.
LMIS	Logistics Management Information System
LMU	Logistics Management Unit
LS	logistics system
MOH	Ministry of Health
MSL	Medical Stores Limited
NVP	Nevirapine
OJT	on-the-job training
PDRIV	PMTCT drug reporting & issue voucher
PEPFAR	U.S. President's Emergency Plan for AIDS Relief
РНО	provincial health office
PMTCT	prevention of mother-to-child transmission
R&R	Report & Requisition
SCC	stock control card
SDP	service delivery point
SOPs	standard operating procedures
ТА	technical assistance
UNFPA	United Nations Fund for Population Activities
TDF/FTC	Tenofovir/Emtricitabine
UNICEF	United Nations International Children's Educational Fund
USAID	U.S. Agency for International Development
ZPCT	Zambia Prevention, Care, & Treatment Project

Acknowledgments

The Ministry of Health would like to thank the following partners for assisting with this assessment and for supporting the ARV Logistics System across the nation: Churches Health Association of Zambia (CHAZ), AIDS-RELIEF, Zambia Prevention, Care and Treatment Project (ZPCT), USAID | DELIVER PROJECT, Center for Infectious Disease Research in Zambia (CIDRZ), and UNICEF. The authors would also like to acknowledge the hospitals and health center staff who participated in this assessment.

The authors would like to express their gratitude to the representatives from the Ministry of Health, USAID |DELIVER PROJECT, and other implementing partners who took time from their busy schedules to participate in ARV LS assessment dissemination meetings. The success of the Zambia national ARV LS program depends on the ongoing collaboration, goodwill, and hard work of all partners if the many challenges of ensuring a continuous supply of quality ARV drugs to the people who need them, and to relieve suffering, are to continue.

Executive Summary

In October 2009, the Ministry of Health with support from the USAID | DELIVER PROJECT conducted a national assessment of the ARV LS. The purpose of the assessment was to evaluate the system's performance since national rollout, identify successes and challenges in the system's implementation, and to provide necessary recommendations for system improvements. The assessment tool used was adapted from the current USAID | DELIVER PROJECT monitoring and evaluation data collection tool.

The major findings indicate that ART satellite sites are the biggest challenge to the system because they are not part of the approved ARV Logistics System. Their operation and existence in the system is not in a standardized format. Each ART satellite site has its way of managing ARV drugs. The non-standardization of these facilities has resulted in none of them capturing essential data items, thus leading to stock imbalances at the facilities from which they have been accessing ARVs.

ART satellite sites need to be included in the system to avert the current stock problems they cause. This inclusion could be accomplished by adding another level to the system. The MOH is willing to authorize the inclusion of satellite sites into the Logistics Management Unit (LMU) database (Supply Chain Manager); however, the sites must provide ART services according to stipulated guidelines while awaiting accreditation by the Health Profession Council of Zambia (HPCZ) and must have staff trained in the logistics system to alleviate stock management problems.

Overview of the ARV Drug Logistics System


The Zambian Government receives funding from the U.S. Government through the President's Emergency Plan for AIDS Relief (PEPFAR), which has allocated for technical assistance in strengthening the supply chain management of ARVs and HIV test kits for national testing and treatment programs. USAID/Zambia selected the USAID | DELIVER PROJECT to provide technical assistance in this area, as well as in the actual procurement of ARVs and HIV test kits through Supply Chain Management System (SCMS). The ARV supply chain in Zambia includes multiple donors, partners, and distribution mechanisms, and efforts to collect specific logistics data on ARV drugs were previously hampered by a poorly functioning logistics management information system (LMIS) and a lack of coordination in managing ARV drugs between cooperating partners.

In May 2006, the Ministry of Health (MOH) designed, with technical support provided by the USAID | DELIVER PROJECT and in collaboration with local stakeholders, a logistics system to improve the flow of logistics information and commodity distribution of ARVs in Zambia. During the national roll-out of this system, it was discovered that certain health facilities that provided prevention of mother-to-child transmission (PMTCT) services but-not full ART, fell outside of the design of this new system. To respond to this exception and incorporate these sites into the newly designed ARV system, the MOH with support from partners developed standard operating procedures (SOPs) and training curricula to implement specialized instructions for addressing the drug logistics needs for these PMTCT-only sites. This system was finalized and approved by the Permanent Secretary as the National PMTCT-Only Drug Logistics System.

System Design and Implementation Plan


In 2005, the Ministry of Health with support from the USAID | DELIVER PROJECT conducted a rapid assessment of the ARV supply chain system. Following the completion of the rapid assessment, and in order to strengthen and to ensure a continuous supply of commodities, the MOH with support from the USAID | DELIVER PROJECT held a workshop in May 2006 with key implementers and stakeholders to re-design the ARV supply chain system. Workshop participants were drawn from all levels in the MOH as well as from cooperating partners. Figure 1 below shows the flow of ARV drugs and information in the national logistics system.

Figure I. Movement of ARV Drugs and Information



A training of trainers (TOT) workshop was held in September 2006. Following, a series of workshops was conducted in the national ARV Logistics System to train participants from all ART sites nationwide. During the initial implementation, 142 facilities throughout Zambia were trained in seven weeks. The Ministry of Health, with support from the USAID | DELIVER PROJECT, has been conducting a series of "mop up" trainings beginning in February 2008, up to the time of the system evaluation. To date, the ARV Logistics System has been rolled-out to almost 200 full ART sites nationally. Figure 2 shows the full ART sites as of October 2009.

Figure 2. 181 Full ART Sites as of October 2009



Purpose of the ARV Drugs Logistics System Assessment

The overall purpose of ARV Drugs Logistics System assessment was to conduct a representative system evaluation. Three key goals were identified for this assessment:

- To assess the ARV Logistics System's performance since its national rollout,
- To identify the successes and challenges in the system's implementation, and
- To provide necessary recommendations for system improvements.

The deliverables from this assessment will be used to create a detailed action plan for the continuous improvement of the existing ARV Logistics System.


Methodology

The assessment activities included preparation, site visits, and presentation of the findings.

During the preparation stage, an assessment tool was developed. The assessment tool was adapted from the current USAID | DELIVER PROJECT's monitoring and evaluation data collection tool. A copy of the final assessment tool is on page 27.

Sites were randomly selected using a web-based software. Twenty percent (20%) of the full ART facilities in each of the nine provinces were assessed. This included eleven (11) hospitals, seventeen (17) health centers, and nine (9) faith-based health facilities – bringing the total number of facilities assessed to thirty seven (37). The sites evaluated are shown in Figure 3.

Figure 3. ART Sites Evaluated



The assessment focused on the following five key areas:

- Human resources
- LMIS records and reports
- Stock status (stock availability)
- Transport
- Storage conditions.

Findings

Human Resources

Figure 4 illustrates the different professional backgrounds of the personnel managing the ARV Logistics System at the various health care levels where ART services are being provided. Nurses account for 30% of the personnel; while pharmacists represent only 5%. A total of 58% represents pharmacy technologists and dispensers. Non-health personal represent 2%; however these have undergone the formal (or OJT) ARV Logistics System training. The assessment revealed that the ARV Logistics System is mainly managed by dispensers, nurses, and pharmacy technologists.




Figure 4. Personnel Managing ARV Logistics System

Every full ART site visited had at least one person formally trained or trained through on-the-job training (OJT). Of the facilities assessed, 54.1% reported to still have the trained personnel on site, while 45.9% were no longer on site. The key reasons provided as to why the personnel trained in logistics were no longer on site were transfers, continuation of studies, etc.

The full ART reporting sites with staff trained in the ARV Logistics System were managing the system well according to the procedures in the standard operation procedures (SOP) manual. The full ART sites without formally trained staff in the system had challenges such as capturing data on LMIS forms.

LMIS Records and Reports

The LMIS records and report findings are categorized by record or report.

Use of Stock Control Cards (SCC)

Of the full ART sites assessed, 97.3% had the SCC for key indicator products. It was observed that facilities without SCC had difficulty explaining how they were generating monthly physical counts from the storeroom to be added to the dispensary physical count during the compilation of the monthly report and requisition (R&R).

Use of Daily Activity Register (DAR)

Only 81.1% of the full ART sites assessed were using the DAR for capturing consumption data as described in the SOP manual. However, the 18.9% who did not use the DAR were using the dispensing tool (software tool) to capture consumption data. Therefore, all full ART sites assessed were using some format of the DAR to capture consumption data.

Report and Requisition (R&R) for ARV Drugs

Of the full ART sites assessed, 81.2% had submitted their September 2009 R&R. The personnel managing the ARV Logistics System have come to appreciate the MOH policy of "*No Report, No Product, No Program*," which has resulted in the continuation of excellent reporting rates with a national average of 98%.

Stock Availability

As shown in Figure 5, there was high stock availability at the full ART sites. SDP staffers understand and appreciate the importance of submitting their R&Rs consistently because MSL replenishes their stocks based on their R&Rs. The facilities that were stocked out of Nevirapine (NVP) 200mg and NVP syrup respectively had the stocks at the DHO pharmacy stores. The stockouts were as a result of:

- No readily available transport to go and pick up drugs from the DHO pharmacy stores.
- Lack of adequate storage space to hold three months of stock (MOS).

However, on the day of the visit, staffers were in the process of arranging for transport to pick up the medical supplies from their respective DHO pharmacy stores.





Figure 5. Stockouts of Indicator Drugs in Full ART Sites

Transport

Facilities collecting ARV drugs from DHO pharmacy stores used various modes of transport as shown in Figure 6. When the health centers collect supplies from the DHO, one of the key means of transport used is public transportation. ARV drugs transported through public transport are at risk in various ways, such as theft, damage, etc.

Figure 6. Distribution and Collection of ARV Drugs



Storage

Of the health centers visited, 48% did not have adequate storage space and could therefore not hold three months of stock. This resulted in some of facilities experiencing stockouts at the facility despite having stock at the DHO pharmacy stores.

ART Satellite Sites: Biggest Challenge to ARV Logistics System


Of the full ART sites assessed, 40% had two or more ART satellite sites. ART satellite sites are facilities that:

- are not accredited as ART sites but provide full ART services;
- are not accessing ARVs directly from the DHO or MSL;
- are not using the standard reporting and ordering system;
- are not in the LMU database; and
- are accessing ARVs through a nearby full ART reporting site.

ART satellite sites are the biggest challenge to the system because they are not part of the approved ARV logistics system. Their operation and existence in the system is not in a standardized format. Each facility of this type has its way of managing ARV drugs, resulting in the non-capturing of essential data items that then lead to stock imbalances at the facilities from which they have been accessing ARVs.

At the time of the assessment, there were more than 200 ART satellite sites in existence. It is against this background that 20 ART satellite sites were assessed using the same tool as the full ART sites. Figure 7 (below) shows the location of the ART satellite sites assessed.

Figure 7. ART Satellite Sites Assessed



Findings from ART Satellite Sites

ART satellite sites shared no uniformity in:

- reporting to their mother facilities;
- capturing essential data items;
- stock availability; and
- use of LMIS forms.

Of the findings above, stock availability was paramount because these facilities are providing ART services that include the dispensation of ARV drugs – hence the need to assess stock availability.




Figure 8. Stockouts of Indicator Drugs at ART Satellite Sites

The assessed satellite sites had experienced stockouts as illustrated in the graph above. The reasons for stockouts were attributed to the following factors:

- Rationing by the parent facility (full ART reporting site).
- Non-inclusion of consumption data from satellite sites in the parent facility's monthly R&R (implying that the re-supply from MSL is only based on data from parent facilities).

Discussion

During the dissemination meeting held in April 2010 at the JSI offices in Lusaka, there were several pertinent issues discussed. Amongst them were the ART satellite sites, as these facilities have had a negative impact on the overall functioning of the system as they do not have standard reporting and ordering procedures.

Impact of ART Satellite Sites on the System

The ARV Drugs Logistics System operations are negatively impacted by the presence of ART satellite sites as they have no standard reporting system. Consumption data from these facilities is not being captured correctly nor consistently on a monthly basis. ARV drugs from mother facilities to satellite facilities are therefore not supplied according to real need and this has lead to either stockouts or overstocks.

Outcome of the dissemination meeting concerning the ART Satellite Sites

- 1. Hold a design workshop to decide on how to include satellite sites in the system to avoid the current stock problems. The USAID | DELIVER PROJECT offered to sponsor this design workshop.
- 2. Specific LMIS forms designed in the medium term to ensure that consumption data, which is also used for national ARV quantification purposes, is recorded correctly. As a way forward, the USAID | DELIVER PROJECT, through their Country Director Walter Proper, offered to sponsor this design workshop.



Dr. Albert Mwango, National ARV Program Coordinator (second from the left), said during the dissemination meeting that, "Since the satellite sites are not part of the approved ARV Logistics System, there is need to include them in the system."



Gail Bryan, Senior Advisor Pharmaceutical Management, ZPCT, echoed that there is need to include the ART satellite sites in the system because of the continued stock imbalances imposed on the full ART reporting sites supplying ARV drugs.



USAID | DELIVER PROJECT Country Director Walter Proper (at the back on the left), categorically stated that his organization was ready to support the MOH by sponsoring the workshop where the inclusion of satellite sites into the ARV Logistics System will be discussed.

Challenges

Human Resources

The MOH's human resources department must take into consideration the special skills of personnel before transferring them so as not to cripple the system. Those that have been trained should ensure that they impart their skills and knowledge to others so that even when they are not at the site or moved to another department, the system will continue to be managed well.

Another challenge has been getting the right cadres to attend the LS trainings. Some districts have working time tables and have therefore been sending people for training who may not be involved in logistics management or may not have the time to administer these systems. This has resulted in training the "wrong" person to manage the system.

Distribution of ARV Drugs

Another challenge is the distribution of drugs to hard to reach areas. CHAZ highlighted that they are and will continue to assist the Ministry in this regard in order to ensure that commodities are delivered to even hard to reach facilities, and they called on others to follow suit in this endeavor.

Mr. Makasa of CHAZ, also committed to be present for all meetings regarding logistics and share information in an effort to unify the system.

Military ART Sites

The military (Major Zulu-ZAF) requested that military facilities also be assessed in order for them to know how they are fairing (for the purposes of feedback). Facilities such as Maina Soko, as well as a few others, could be accessed with prior permission. JHPIEGO, through JSI/LS, has been working with defense forces to design logistics systems for ARVs and HIV tests kits. These systems have been running for a short period of time and an assessment has been planned.

Conclusion and Recommendations

Satellite Sites

Considering the negative effects of satellite sites on logistics management at full ART reporting sites, these sites should be included in the system design, and their accreditation process should be expedited. In order for the MoH to authorize inclusion of a satellite site into the LMU database, the site must provide ART services according to stipulated guidelines while awaiting accreditation by MCZ, and have staff trained in the logistics system to alleviate stock management problems.

During the dissemination meeting, it was agreed that a design workshop would be held to develop a strategy for incorporating ART satellite sites into the system to avert the current stock problems caused by their existence. The time frame as to when the workshop will be held was not agreed upon, though it was agreed that it should be soon. In support of the MOH, the USAID | DELIVER PROJECT's Country Director, Walter Proper, offered to sponsor this design workshop.

Supervision

Supervision should be strengthened with particular focus on logistics functions; i.e., ensuring that facilities are stocked according plan in order to reduce stock imbalances. The MOH will take the

lead in this activity, with the PHOs, DHOs, and SDP levels working in collaboration with implementing partners such as CHAZ, CIDRZ, and ZPCT.

Training

There is a need for formally training more staff from facilities where all trained staff have since left. The MOH in collaboration with the USAID | DELIVER PROJECT will continue conducting mop up trainings to cater to untrained staff.

Transport

Considering that there are some facilities that have been using public transport to move ARV drugs from the DHOs to their respective health facilities, there is a need for DHOs to have a fixed schedule for drug distribution to health centers and dedicated transport for drug distribution to enhance ARV drug availability.

Storage

There is a need for facilities to utilize available space, such as larger rooms being used for other supplies. The facilities with inadequate storage space must look into the possibility of expanding so that they are able store 3 months of stock. Subsequently, there will be reduction in stockouts that occur as a result of facilities having part of their stock kept at DHO pharmacy stores.

In collaboration with cooperating partners, the MOH should develop guidelines on storage space management which can be used by SDP levels with limited and alternative storage space. The USAID | DELIVER PROJECT is supporting the MOH by conducting storage assessments for facilities that include cost estimates.

References

Addo, Nii Akwei, Rowland Adukpo, Veronica Bekoe, Samuel Boateng, Ronald Brown, Egbert Bruce, Aoua Diarra, Parfait Edah, Wendy Nicodemus, Festus Sroda. 2006. *Assessment of the Ghana Laboratory Logistics System and Services*. Arlington, Va.: DELIVER, for the U.S. Agency for International Development (USAID).

Hasselberg, Erin and Peter Lisulo. 2008. Zambia: PMTCT-Only Drug Logistics System Assessment Results And Recommendations. Arlington, VA: USAID | DELIVER PROJECT, Task Order 1. Appendix A

LMIS Forms

ARV Drug Stock Control Card



	CODE	E:
ITEM DESCRIPTION:	STRENGT	Н
		:
UNIT:		
MAXIMUM LEVEL:	MINIMUM LEVEL:	(Reorder Level)

DATE	REF. No.	ISSUED TO OR RECEIVED FROM	RECEIVED (+)	ISSUED (-)	LOSSES and ADJUST- MENTS	BALANCE	UNIT PRICE	NAME/ SIGNATURE	REMARKS



																			-	- 41 - 71																						
																		TRYC				_																				
															A	RT D	AILY	ACTI	VITY			R Dispen																				
			F	ixed Dose	e Combi	inations										Single	Drug I	ormula	itions	Quar	nnes	Dispen	 Liquid/Powder Formulations																			
Fac	ility:	irapine															Ĵ																									ials
Dist	trict:	dine/Nev	s s dine	dine	abine 30	udine				sd									or 60)	or 60)	or 60)							tion	olution	olution	- voi a la constra	niciiade	spension	spensiol	for susp.	for susp	olution	o lu tio n				's Init
Date	Patient Name/Number	Stavudine/Lamivudine/Nevirapine 30/150/200mg Tabs 5 Anthe of 60 minudine/Noviranio	Stavuoinella mivuoine/Nevirapine 4.0/15.0/2.00 mg Tabs Bottle of 60 Tabs Stavurdinella mivudine	301/50mg Tabs 301/50mg Tabs Bottle of 6. Tabs Stay udine 401/50mg Tabs	Bottle of 60 Tabs Tenofovir/Emitrict tablets	Bottle of 30 tablets Zidovudine/Lamiv 300/150 mg Tabs Bottle of 60 Tabs		A bacavir 300 mg Tabs Bottle of 60 Tabs	Efavirenz 200 mg Cap s Bottle of 90 Cap s	E favirenz 50 m g Caps Bottle of 30 Caps	E favirenz 600 mg Tabs Bottle of 30 Tabs	Didanosine 100 mg Tabs Bottle of 30 Tabs	Didanosine 25m g Tabs Bottle of 60 Tabs	Didanosine 50m g Tabs Bottle of 60 Tabs	Lamivudine 150 mg Tabs Bottle of 60 Tabs	Lopinavir/ritonavir 133.3/33.3mg Bottle of 180 Caps	Nevirapine 200 mg Tabs Bottle of 60 Tabs	Stavudine 15mg Caps Bottle of 60 Caps	Stavudine 20m g Caps Bottle of 56 Caps	Stavudine 30m g Caps Bottle of 56 Caps (or 60)	Stavudine 40m g Caps Bottle of 56 Caps	Tenofovir 300 mg Tabs Bottle of 30 Tabs	Zidovu dine 100 mg Cap s Bottle of 60 Cap s	Zidovu dine 300 mg Tabs Bottle of 60 Tabs				A bacaviroral solu 2.0 mg/ml 2.40 ml Bottle	Lamivudine orals 10mg/ml 100ml Bottle	Lamivudine orals 10mg/ml 240ml Bottle	Lop in a vir/riton a vir 20 mg/80 mg/ml 60 m f bottle Naviratina o vial su sonasian	10m g/m l	N evirapine oral su 10m g/m l 2.40m l Bottle Novironin o oral ou	N evira pin e oral su 10m g/m I (PMTCT) 25m I Bottle	Nelfinavir powder 50mg/g 144.0 Bottle	Stavudine powder 1 mg/m l 200 m o Bottle	Zidovudine Oral S 10mg/ml 240ml Bottle	Zidovudine Oral S 10mg/ml 100ml Bottle				Dispenser's Initials
					_		_	-																																		
			_				_																					_			_	_	_							_		
																																								_		
			_	_	+		_													_					_	_			_			_	+		_				_	—	_	
																_																										
																																								_		
				_			_	-																	_	_		_	_		_	_	_		_					_	_	
				_	-		-																		_	_		_	_		_	_	-		_				_	—	_	
																																	_									
-		+		+			+																		\rightarrow	+		\rightarrow	\rightarrow			+	+	-						+	+	
			_				_																				-						+							+	_	
-		+																									┥┢						+							-		
Qua	al Quantity Dispensed Intity Dispensed for Month Ining total):																																							\pm		



												MINIC																				
											ARI	DAIL	ACTIV	VIIY	REGIS Quantit		nensed															
		Fix	ed Dose Com	binations							Sing	gle Drug	Formula	tions	Quarta		ponoou									id/Powo						
Fac	ility:	a bind a									als																					
Dist	trict:	Savudine/Lam/jvudine/Nevirapine 30/150/200mg Tabs Bould of Raf Tabs Bould of Raf Tabs Bould of Raf Tabs Savud of Raf Tabs Savud of tabs Savud of tabs	autric de la contraction de la																													
		am iv ud Tabs Tabs Tabs Tabs Tabs	aps Tabs am ivud abs Tabs mitricta	tablets /Lamivu Tabs Tabs		S Tabs	omg Ca Caos	s Tabs	Tabs	Tabs	s Tabs Itonavir	o caps	Caps	Caps (c	Caps for	Caps (c	S Tabs	Caps S Tabs		al solut	e e oral so	e oralso e	itonavir /m l	oral sus e oral sus	e e oraisus	MTCT) owderf	owderf	le Oral So	e Oral So e			nser'
		vu dine/l 150/2001 ttle of 60 1 vu dine/l 150/200 ttle of 60 vu dine/l	ttle of 60 vu dine/L 150 mg T ttle of 60 vo fovir/E	ttle of 30 ovudine 0/150mg ttle of 60		Abacavir 300m g Tabs Bottle of 60 Tabs Efavirenz 200m g Caps	E favirenz 50 mg Caps Bottle of 30 Caps E favirenz	600 m g Tabs Bottle of 30 Tabs Didanosine 100 m g Tabs	ttle of 30 a nosine ng Tabs ttle of 60	anosine ng Tabs ttle of 60	Lam ivudine 150m g Tabs Bottle of 60 Tabs Lopinavir/ritonavir 133.3/33.3 m g	Bottle of 180 Cap Nevirapine 200 mg Tabs	Stavudine 15 mg Caps Bottle of 60 Caps	ita vu dine 0 m g C ap s lottle of 56 C ap s (or 60)	Stavudine 30 mg Caps Sottle of 56 (Stavudine	10 mg Caps 3ottle of 56 Caps (or 60) Cenofovir	300 m g labs Bottle of 30 Tabs Zidovudine 100 m o Cabs	Bottle of 60 Caps Zidovudine 300mg Tabs Bottle of 60 Tabs		acavir or	ng/m Bottl nivudine ng/m	brof Bottl nivudine ng/m l Drof Bottl	Lopin avir/ritona vir 20 m g/8 0 m g/m 1 60 m f bottle	virapine ng/ml bmlBottl	virapine ng/m l Dm l Bottl virapine	n g/m l (P n l Bottle lfinavir p	vu dine p vu dine p g/m l	ovudine ng/ml)m Iboru ovudine ng/m l nm I Borti			D is pe
Date	Patient Name/Number	800 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1 B 4 0 8 0	Z id 301 80	+	A D 2008 2008 2008	800 110 110 110 110		Dic 25 80	900 800	120 120 130 130 130	SOC B	Sta 15-15 B0	S 12 80 80	S 10 0 12 0 12 0 12 0 12 0 12 0 12 0 12	H B C	2 I I I	301d 301d B0		4 P	10 10	10 10 24	200 200	900 S	24 Ne Ne	22 Ne Ne	24 50 13 E	2 J 0	2 id	\vdash		-
⊢		+ $+$ $+$		+			\vdash	+					\vdash													+			+	\vdash		+-
																													\square	Щ		
							\vdash												 _						_					\vdash		
								_	_								_		_		_	-			_	_	_		+	\vdash		
																										-			+			
																													\square			
																			_											\vdash		_
															_		_		_		_				_	_	_		+	\vdash		
									+	_	_						-		-		+				-	-			+	┢─┼╴		-
																													\square		-	
																														\square		
								_									_		_		_				_	_	_		+	\vdash		-
		+ $+$ $+$					\vdash	+	+				$\left \right $				+				+				+	+		-	+	┢━╋	_	+
-								+	+								+				+				+	+			+	\vdash		+
																				Í												
																				┥┝										\square		
	tal Quantity Dispensed																															
	ntity Dispensed for Month ning total):																													Ш		



REPORT AND REQUISITION FOR ANTIRETROVIRAL DRUGS

Emergency Order

Reporting Period: Fro	omdd/mm/yy	yy to	dd/mm/yyyy	Province:			Maximu	m Stock Level:	3 Months
Facility:				District:			Emergenc	y Order Point:	0.5 Months
Drug Product	Unit	Beginnin g Balance of Store room + Dispensa ry	Total Quantity Received during the month	Total Quantity Dispensed for the month	Losses and Adjustments	Physical Count of Store Room + Dispensary at the end of the month	AMC = (E + previous 2 months consumption) ÷ 3	Maximum Quantity	Order Quantity
Α	В	Č	D	E	F	G	Н	I = (H X 3)	J = (I-G)
Single Drug Formulations									
Efavirenz	Bottle of 30								
50mg Capsules	Capsules								
Efavirenz	Bottle of 90								
200mg Capsules	Capsules								
Efavirenz	Bottle of 30								
600mg Tablets	Tablets								
Lamivudine	Bottle of 60								
150mg Tablets	Tablets Bottle of 180								
Lopinavir/ritonavir 133.3/33.3mg Capsules	Capsules								
Nevirapine	Bottle of 60								
200mg Tablets	Tablets								
Stavudine	Bottle of 60								
15mg Capsules	Capsules								
Stavudine	Bottle of 56								
20mg Capsules	Capsules (or 60)								
Stavudine	Bottle of 56								
30mg Capsules	Capsules (or 60)								
Stavudine	Bottle of 56								
40mg Capsules	Capsules (or 60)								
Tenofovir	Bottle of 30								
300mg Tablets	Tablets								

Explanation for Losses/Adjustments:

Remarks:

26



REPORT AND REQUISITION FOR ANTIRETROVIRAL DRUGS

Emergency Order

and the field of the second										
Reporting Period: From	L	to		Province:			Maximu	m Stock Level:	3 Months	
1 0	dd/mm/	/vvvv	dd/mm/yyyy	- –						
	, ,		, , , , , , , , , , , , , , , , , , , ,							
									Manula	
Facility:				District:			Emergenc	y Order Point:	0.5 Months	
Drug Product	Unit	Beginning	Total	Total Quantity	Losses and	Physical Count	AMC =	Maximum	Order Quantity	
		Balance of	Quantity	Dispensed for the	Adjustments	of Store Room	(E + previous	Quantity	-	
		Store room	Received	month		+ Dispensary at	2 months	-		
		+	during the			the end of the	consumption)			
		Dispensary	month			month	$\div 3$			
Α	В	C	D	E	F	G	Н	I = (H X 3)	J = (I-G)	
Single Drug Formulations	•							· · · · ·	· · · · · · · · · · · · · · · · · · ·	
Zidovudine	Bottle of									
100mg Capsules	100 Capsules									
Zidovudine	Bottle of 60									
300mg Tablets	Tablets									_
Liquid/Powder Formulations										
Abacavir oral solution 20mg/ml	240ml Bottle									
Lamivudine oral solution 10mg/ml	100ml Bottle									
Lamivudine oral solution 10mg/ml	240ml Bottle									
Lopinavir/ritonavir 20mg/80mg/ml	60ml bottle									
Nelfinavir powder for suspension 50mg/g	144g Bottle									
Nevirapine oral suspension 10mg/ml	100ml Bottle									
Nevirapine oral suspension	240ml Bottle									

Explanation for Losses/Adjustments:

Remarks:



REPORT AND REQUISITION FOR ANTIRETROVIRAL DRUGS

Province:

Emergency Order

Maximum Stock Level: 3 Months

Emergency Order Point: **0.5** Months

Reporting Period:	From

dd/mm/yyyy

/vvvv

Facility:

District:

Drug Product	Unit	Beginning	Total	Total Quantity	Losses and	Physical Count	AMC =	Maximum	Order
_		Balance of	Quantity	Dispensed for the	Adjustments	of Store Room	(E + previous	Quantity	Quantity
		Store room	Received	month		+ Dispensary	2 months	-	
		+	during the			at the end of	consumption)		
		Dispensary	month			the month	÷ 3		
Α	В	С	D	E	F	G	Н	I = (H X 3)	J = (I–G)
Liquid/Powder Formulations									
Nevirapine oral solution 10mg/ml (PMTCT)	25 ml Bottle								
Stavudine powder for suspension 1mg/ml	100ml Bottle								
Zidovudine oral solution 10mg/ml	240ml Bottle								
Zidovudine oral solution 10mg/ml	100ml Bottle								

Explanation for

Losses/Adjustments:

Remarks:

Completed by: Signature:

Date:

Authorized by:

Signature:

Date:

nature: ______

Authorized by:

Signature:

Date:

28

SUPPLY VOUCHER (Health Centre) for ARV Drugs

To (Name	e of District Stores):			From (Name	of Centre/Unit/D	Dept):	_	
Requested	1 by:Signature:	D	ate:					
Authorise	d by:Signature: Dat	e:						
(A) Item Code	(B) Description, Strength, Form	(C) Unit	(D) Balance at Hand	(E) Quantity Requested	(F) Quantity Supplied	(G) Quantity Received	(H) Balance on Hand at District	(I) Remarks
Approved	by:	Issued by:		De	elivered by:		Received by:	
Date:		Date:		Da	ate:		Date:	

Computer Generated Report and Requisition for Antiretroviral Drugs

Report Peri Facility: Code:	iod: August, 2006 Mother Theresa Hospital 8476352				Maximum Stoc mergency Ordo		0.0 months 0.5 months				
Product		Unit	Beginning Balance	Total Quantity Received	Total Quantity Dispensed	Adjust- ments	Physical Count	AMC	New EOP	Order Quantity	Quantity Supplied
FDC004	Stavudine/Lamivudine 40/150mg Tablets	Bottle of 60	0.00	200.00	150.00	50.00	100.00	150.00	75.00	350.00	350.00
FDC005	Zidovudine/Lamivudine 300/150mg Tablets	Bottle of 60	0.00	300.00	20.00	-100.00	180.00	20.00	10.00	0.00	0.00
FD006	Tenofovir/Emitricitabine 300/200mg Tablets	Bottle of 60	0.00	200.00	150.00	50.00	100.00	150.00	75.00	350.00	350.00
SDF001	Efavirenz 50mg Capsules	Bottle of 30	0.00	200.00	150.00	50.00	100.00	150.00	75.00	350.00	350.00
	Computer Generated Adjustment of -200 Dn 08-28-2006 at 22:51:25 for 0 Computer Generated Adjustment of 50 Dn 08-30-2006 at 16:22:48 for Stavudine/Lamivudine 40/150 Computer Generated Adjustment of 50 Dn 08-30-2006 at 23:59:11 for Tenofovir/Emitricitabine 300/ Computer Generated Adjustment of 50 Dn 08-31-2006 at 00:32:07 for Efavirenz 50mg Capsules	0									
	MU Technical Officer Signature & Name								Date Date		

Appendix B

Data Collection Forms

ARV Logistics System

Evaluation Data Collection Tool

FACILITY IDENTIFICATION	
Facility Name: Province:	Prov. Dist. Fac. Facility Code:
District :	
Type of Site (Check what applies): ART ART Satellite Operating Authority: MOH NGO (list NGO) Mission	Facility (SDP) Type: Hospital Level 3 Hospital Level 2 Hospital Level 1 Health Centre Cooperating Partner Support: CHAZ ZPCT CIDRZ AIDS Relief Other (Specify)
INFORMATION ABOUT EVALUATION Date of visit: DAY/ MONTH/ YEAR Image: Comparison of the second secon	Name/title of the staff member(s) interviewed:

Trai	ning		
No.	Question	Code Classification	Go To
1	Who is the principal person responsible for managing ARVs at this facility?	 Nurse Clinical Officer Pharmacist Pharmacy Technologist Dispenser Other (Specify) 	
2	Have they received the ARV Logistics System training?	Yes1 No0	
3	Has anyone in this facility received On-the-Job training in the ARV Logistics System?	Yes1 No0	
4	When the trained person is out of the facility, who then completes the reports?		
5	Is there a copy of the SOP Manual for the ARV Logistics System at the facility? (ask to be shown the manual)	Yes1 No0	
LM	IS Records and Reporting (circle all that apply)	
6A	Is the facility using the Daily Activity Register for ARVs?	Yes1 No0	→ 7
6B	If no to 6A, what does the facility use?	Dispensing tool	
7	When was the last time an ARV report/order submitted from this facility?	Never0Within the last month1More than 1 month ago2More than 2 months ago3More than 3 months ago4	
8	How long does it take to complete the report/order?	1hour1 2hours2 3hours3 Other4	
9	How do you transmit your report/order to the next higher level?	Radio1 Phone2 Posting3 Other4	
10	On average, how long does it take between ordering and receiving ARVs?	Less than 2 weeks12 weeks to one month2Between 1 and 2 months3More than 2 months4	
11	How many emergency orders for ARV's have you made in the last six months?	One1 Two2 Three3 Four4	

		None5
12	Do you always receive the quantities of ARV drugs that you order?	Yes1 No0
13	Do you receive the computerized R&R when you receive your order from the district?	Never0Always1Sometimes2

Trans	port		
14	Who is responsible for transporting ARVs to your facility? CIRCLE ALL THAT APPLY	MSL delivers A District delivers B This facility collects C Other (Specify)	
15	What kind of transportation is most often used?	Facility vehicle1Public transportation2Private vehicle3Boat4Motorcycle5Bicycle6On foot7Other (Specify)9	
16A	Have you stocked out of any of the ARV's (indicator products) in the last six months?	Yes1 No0	→ 17
16B	If yes to 16A, how many times?	Once1 Twice2 Three times3 Four times4	
17	Has the facility experienced any problems with the ARV Logistics System?	Monthly ordering cycle	
18	Do you have any specific recommendations for improving the ARV Logistics System?		
ACCU	IRACY OF LMIS RECORDS		
A. I	DAILY ACTIVITY REGISTER		
19	On average, how many months of supply of ARVs do you dispense to a client?	A month1 Two months2 Three months3	

20A	Is the data in the DAR tallied at the bottom of each page?	Yes1	→g o to 21
20B	If no to 20A, why?	Check any that apply: Lack of training Absence from work Forgetting to do so Overwhelmed with work Other:	
21	Is the DAR tallied at the end of each month? If no, how is the total quantity dispensed calculated at the end of the month for inputting onto the R&R?	Yes1 No0	
22	Is the data on the DAR entered on a daily basis up to the day of the visit?	$ \begin{array}{ c c c c c } \square & Yes1 \\ \square & No0 \end{array} $	→ 2 4
23	If no to 22, why?	Check any that apply: Lack of training Absence from work Forgetting to do so Overwhelmed with work Other:	
24	Is data transposed accurately from the DAR to the Quantity Dispensed/Used column on the most recent R&R? If no, why?		→ 26
25	If answered "yes" to question #24, check the according the following: 1. Note the month of the last R&R 2. Note the total from the last day of the DA 3. Note the quantity reported dispensed/user the facility AND the Computerized R&R Product DAR Total from Last Da Month D4T 30/3TC/NVP	AR for the R&R for that month (from the copy a from SCMgr)	y at

	TDF/FTC								
	EFV 600mg								
	NVP 200mg								
	NVP Solution 240mls								
B. STOCK CONTROL CARDS									
26	Is there a SCC available for each p this facility? (Confirm only for the being assessed)	product areas	1 0						

1. Check the stock availability and accuracy of the SCC

Product	this ou Facility? toda		Stock SCC out Available? oday? (Y/N) (Y/N)	Calculated Physica Balance on Count SCC	Physical Count	Quantity Expired	Quantity Supplied (Source: Last R&R)	Quantity Received (Source: SCC after R&R)	General Comments
А	В	С	D	E	F	G	H	I	
D4T 30/3TC/NVP									
TDF/FTC									
EFV 600mg									
NVP 200mg									
NVP Solution 240mls									

С	C. REPORT AND REQUISITION					
28	Does the quantity supplied on R&R equal the quantity received on the stock control card for key indicator products (column H=I in question 27)? If no, why was there a discrepancy?	Yes1 No0				
29	Do you have satellite sites that you are supporting?	Yes1 No0 If no ignore the following questions.				
30	Is the data on your R&R inclusive of Satellite Sites?	Yes1 No0	→32			
31	Do your satellite sites have LMIS materials for data collection?	Yes1 No0	→33			
32	How do you account for the drugs that you give to them?					
33	How do you collect the reports from the satellite sites?	Satellite site sends1 Facility collects2 Not Applicable0				

TABLE 3: Drug Storage Conditions (only assess main store)

Assess storage condition of main storage area <u>only.</u> Place a "Y" for yes or "N" for no in the appropriate column based on visual inspection of the storage facility; note any relevant observations in the comments column. To qualify as "yes," all products and cartons must meet the criteria for each item.

No	Description	Y/N	COMMENTS
01.	Products are stored and organized in a manner accessible for first-to-expire, first-out (FEFO) counting and general management.		
02.	Does the facility makes it a practice to separate damaged and/or expired products from usable products and removes them from inventory?		
03.	Are medicine stored separately from insecticides and chemicals?		
04.	Is the current space and organization sufficient for existing products and reasonable expansion (i.e., receipt of expected product deliveries for foreseeable future)? Is space appropriate?		
05.	There is no evidence of rodents or insects in the storage area. (Visually inspect the storage area for evidence of rodents [droppings] or insects that can damage or contaminate the products.)		
06.	Storage area is secured with a lock and key, but is accessible during normal working hours; access is limited to authorized personnel.		
07.	Products are protected from direct sunlight on the day of the visit.		
08.	Products are stored at the appropriate temperature on the day of the visit according to product temperature specifications.		
09.	Is there appropriate fire safety equipment? If fire extinguisher, is it serviced?		
10.	Are there pallets/shelves available to ensure products are off the floor?		
11.	Are products stored 30cm off the wall, 10 cm from the floor (where appropriate)? Are products stacked not more than 2.5 cm high?		

For more information, visit deliver.jsi.com.

USAID | DELIVER PROJECT

John Snow, Inc. 1616 Fort Myer Drive, 11th Floor Arlington, VA 22209 USA Phone: 703-528-7474 Fax: 703-528-7480 Email: askdeliver@jsi.com Internet: deliver.jsi.com